PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: IMARC Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

The Market for Biopharmaceuticals Worth USD 101 Billion in 2010 Finds IMARC Group - A new report from IMARC Group expects that driven by factors such as a strong pipeline and ability to treat diseases with high unmet needs, the global market for biopharmaceuticals is expected to reach revenues worth US$ 167 Billion by 2015
The Market for Biopharmaceuticals Worth USD 101 Billion in 2010 Finds IMARC Group

 

NewswireToday - /newswire/ - Delhi, India, 2011/08/01 - A new report from IMARC Group expects that driven by factors such as a strong pipeline and ability to treat diseases with high unmet needs, the global market for biopharmaceuticals is expected to reach revenues worth US$ 167 Billion by 2015.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Global Biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. IMARC Group, one of the world’s leading research and advisory firms, in its new report entitled “Global Biopharmaceutical Market Report (2010-2015)” finds that more than three hundred biopharmaceuticals have already been approved and many more are in late stage clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases, but have also provided the thrust for the continued success of the pharmaceutical industry.

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition and out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry’s USD 101 Billion figures and double digit growth rates in the last five years are a testimonial to the fact that the ones that finally do get approval represent goldmines for investors.

Key Aspects Analyzed in This Report:

Evaluating the Critical Success and Risk Factors Operating in the Global Biopharmaceutical Market:
Focus of the analysis:

• An Insight on the Key Strengths of the Global Biopharmaceutical Market;
• An Insight on the Key Weaknesses of the Global Biopharmaceutical Market;
• Evaluating the Key Opportunities for the Global Biopharmaceutical Market;
• Evaluating the Key Threats faced by the Global Biopharmaceutical Market;

Comprehensive Situation Analysis of the Global Biopharmaceutical Market:
Focus of the analysis:
• Evaluating the Historical, Current and Future Market Performance
• Evaluating The Historical, Current and Future Market Performance by Region
• Evaluating The Historical, Current and Future Market Performance by Biological Class
• Evaluating the Market Performance by Indication
• Evaluating the Performance of Major Biopharmaceutical Manufacturers
• Evaluating the Performance of Major Biopharmaceutical Brands

An In-depth Analysis of Various Developed and Emerging Biopharmaceutical Markets:
Countries Covered: US, Germany, Japan, France, Italy, Spain, United Kingdom, Canada, Russia, China, Australia, Turkey, Mexico, South Korea, India, Brazil, Argentina and Indonesia.
Biological Classes Covered for Each Country: Recombinant Proteins, Insulin, Erythropoietins, Interferons, Colony Stimulating Factors, Immunoglobulins, Recombinant Blood Factors, Growth Hormones, Recombinant Enzymes, Interleukins, Growth Factors, Monoclonal Antibodies and Purified Proteins.
Focus of the analysis in each country:
• Evaluating the Historical, Current and Future Market Performance
• Evaluating the Performance by Biological Classes
• Evaluating the Performance of Major Biopharmaceutical Manufacturers

Table of Contents:
1. Market Definitions & Research Methodology
2. Analyst Briefing
3. Introduction to Biopharmaceuticals
4. Global Biopharmaceutical Market: Industry Analysis
4.1 Strengths
4.1.1 High Efficacy and Target Oriented Attack
4.1.2 Strong Potential to Achieve Blockbuster Status
4.1.3 Limited Generic Threat
4.1.4 Approval Success Rates are Higher than Small Molecule Drugs
4.2 Weaknesses
4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives
4.2.2 Second Line of Therapy
4.2.3 Huge Cost of Therapy
4.2.4 High Incidence of Unfavorable Side Effects
4.3 Opportunities
4.3.1 Diseases with High Unmet Needs
4.3.2 Expanding the Patient Pool by Approval into Additional Indications
4.3.3 Emerging Markets
4.3.4 Increasing New Approvals and a Strong Pipeline
4.4 Threats
4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
4.4.2 Biosimilars
4.4.3 Limited and Conditional Reimbursement
4.4.4 Uncertainties in the Economic Environment
5. Global Biopharmaceutical Market: Industry Performance
5.1 Market Performance & Forecast
5.1.1 Current Performance (2005-2009)
5.1.2 Market Forecasts (2010-2015)
5.2 Market Segmentation by Region
5.2.1 Current Performance (2005-2009)
5.2.2 Market Forecasts (2010-2015)
5.3 Market Segmentation by Indication
5.4 Market Segmentation by Class
5.4.1 Recombinant Proteins
5.4.2 Monoclonal Antibodies
5.4.3 Purified Proteins
5.5 Competitive Landscape
5.5.1 Top Biopharmaceutical Players
5.5.2 Top Biopharmaceutical Drugs
6. North America
6.1 US
6.1.1 Market Performance (2005-2009)
6.1.2 Market Segmentation by Class
6.1.3 Performance of Top Players
6.1.4 Market Forecasts (2010-2015)
6.2 Canada
6.2.1 Market Performance (2005-2009)
6.2.2 Market Segmentation by Class
6.2.3 Performance of Top Players
6.2.4 Market Forecasts (2010-2015)
7. Latin America
7.1 Mexico
7.1.1 Market Performance (2005-2009)
7.1.2 Market Segmentation by Class
7.1.3 Performance of Top Players
7.1.4 Market Forecasts (2010-2015)
7.2 Brazil
7.2.1 Market Performance (2005-2009)
7.2.2 Market Segmentation by Class
7.2.3 Performance of Top Players
7.2.4 Market Forecasts (2010-2015)
7.3 Argentina
7.3.1 Market Performance (2005-2009)
7.3.2 Market Segmentation by Class
7.3.3 Performance of Top Players
7.3.4 Market Forecasts (2010-2015)
8. Europe
8.1 Germany
8.1.1 Market Performance (2005-2009)
8.1.2 Market Segmentation by Class
8.1.3 Performance of Top Players
8.1.4 Market Forecasts (2010-2015)
8.2 France
8.2.1 Market Performance (2005-2009)
8.2.2 Market Segmentation by Class
8.2.3 Performance of Top Players
8.2.4 Market Forecasts (2010-2015)
8.3 Italy
8.3.1 Market Performance (2005-2009)
8.3.2 Market Segmentation by Class
8.3.3 Performance of Top Players
8.3.4 Market Forecasts (2010-2015)
8.4 Spain
8.4.1 Market Performance (2005-2009)
8.4.2 Market Segmentation by Class
8.4.3 Performance of Top Players
8.4.4 Market Forecasts (2010-2015)
8.5 UK
8.5.1 Market Performance (2005-2009)
8.5.2 Market Segmentation by Class
8.5.3 Performance of Top Players
8.5.4 Market Forecasts (2010-2015)
8.6 Russia
8.6.1 Market Performance (2005-2009)
8.6.2 Market Segmentation by Class
8.6.3 Performance of Top Players
8.6.4 Market Forecasts (2010-2015)
8.7 Turkey
8.7.1 Market Performance (2005-2009)
8.7.2 Market Segmentation by Class
8.7.3 Performance of Top Players
8.7.4 Market Forecasts (2010-2015)
9. Asia Pacific
9.1 Japan
9.1.1 Market Performance (2005-2009)
9.1.2 Market Segmentation by Class
9.1.3 Performance of Top Players
9.1.4 Market Forecasts (2010-2015)
9.2 China
9.2.1 Market Performance (2005-2009)
9.2.2 Market Segmentation by Class
9.2.3 Performance of Top Players
9.2.4 Market Forecasts (2010-2015)
9.3 Australia
9.3.1 Market Performance (2005-2009)
9.3.2 Market Segmentation by Class
9.3.3 Performance of Top Players
9.3.4 Market Forecasts (2010-2015)
9.4 South Korea
9.4.1 Market Performance (2005-2009)
9.4.2 Market Segmentation by Class
9.4.3 Performance of Top Players
9.4.4 Market Forecasts (2010-2015)
9.5 India
9.5.1 Market Performance (2005-2009)
9.5.2 Market Segmentation by Class
9.5.3 Performance of Top Players
9.5.4 Market Forecasts (2010-2015)
9.6 Indonesia
9.6.1 Market Performance (2005-2009)
9.6.2 Market Segmentation by Class
9.6.3 Performance of Top Players
9.6.4 Market Forecasts (2010-2015)

To buy the complete report or to get a free sample, please call or visit imarcgroup.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


The Market for Biopharmaceuticals Worth USD 101 Billion in 2010 Finds IMARC Group

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IMARC Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  1Click Games

Visit  Intrinsic Executive Search Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)